HIM
IPXL

Hillsdale Investment Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Hillsdale Investment Management’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-58,200
Closed -$1.18M – 553
2017
Q3 		$1.18M Buy
+58,200
New +$1.11M 0.2% 108

Other funds holding IPXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TG
TCW Group Los Angeles, California $14.9B AUM 46.29% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Hillsdale Investment Management's IPXL Position: Q4 2017 in Review

Hillsdale Investment Management sold out of Impax Laboratories, Inc. (IPXL) in Q4 2017, closing a stake of 58,200 shares — an estimated $1.18M sold.

Hillsdale Investment Management first reported a position in IPXL in Q3 2017 and held it in 1 quarter. The position peaked at $1.18M in Q3 2017. 200 funds tracked by Wall St. Rank hold IPXL as of Q4 2017.

  • Hillsdale Investment Management reported no remaining Impax Laboratories, Inc. position as of Q4 2017 after selling out during the quarter.
  • Hillsdale Investment Management sold 58,200 Impax Laboratories, Inc. shares in Q4 2017, an estimated $1.18M.
  • Hillsdale Investment Management first reported a position in Impax Laboratories, Inc. in Q3 2017 and held it in 1 quarter.
  • Hillsdale Investment Management's Impax Laboratories, Inc. position peaked at $1.18M in Q3 2017.
  • 200 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2017.

Based on Hillsdale Investment Management's 13F filing for Q4 2017, filed 13 Feb 2018.